237 related articles for article (PubMed ID: 2769847)
41. Long term protection in bladder cancer following intralesional immunotherapy.
Reichert DF; Lamm DL
J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
[TBL] [Abstract][Full Text] [Related]
42. Intravesical therapy for superficial bladder cancer.
Malkowicz SB
Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
[TBL] [Abstract][Full Text] [Related]
43. BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer.
Bassi P
Surg Oncol; 2002 Jun; 11(1-2):77-83. PubMed ID: 12031870
[TBL] [Abstract][Full Text] [Related]
44. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
[TBL] [Abstract][Full Text] [Related]
45. Oral or intravesical bacillus Calmette-Guerin immunoprophylaxis in bladder carcinoma.
D'Ancona CA; Netto Júnior NR; Claro JA; Ikari O
J Urol; 1991 Mar; 145(3):498-501. PubMed ID: 1997698
[TBL] [Abstract][Full Text] [Related]
46. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
47. Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin (BCG) immunotherapy exist?. analysis of a quarter century of literature.
Saint F; Salomon L; Quintela R; Cicco A; Hoznek A; Abbou CC; Chopin DK
Eur Urol; 2003 Apr; 43(4):351-60; discussion 360-1. PubMed ID: 12667715
[TBL] [Abstract][Full Text] [Related]
48. Immunoprophylaxis of superficial bladder cancer: a prospective and randomized comparison of oral versus intravesical Bacillus Calmette-Guerin.
Netto Júnior NR; Levi d'Ancona CA; Claro JF; Ilari O
Arch Esp Urol; 1991 Oct; 44(8):1025-8. PubMed ID: 1796850
[TBL] [Abstract][Full Text] [Related]
49. Ureteral carcinoma in situ after successful intravesical therapy for superficial bladder tumors: incidence, possible pathogenesis and management.
Herr HW; Whitmore WF
J Urol; 1987 Aug; 138(2):292-4. PubMed ID: 3599241
[TBL] [Abstract][Full Text] [Related]
50. Bacillus Calmette-Guérin immunotherapy. Techniques and results.
Brosman SA
Urol Clin North Am; 1992 Aug; 19(3):557-64. PubMed ID: 1636239
[TBL] [Abstract][Full Text] [Related]
51. Experience with bacillus Calmette-Guérin in patients with superficial bladder tumors. Value of monocyte activation in intravesical bacillus Calmette-Guérin therapy.
Nissenkorn I; Lavie G; Keisari Y; Leib Z; Vilcovsky E; Servadio C; Shachter H
Eur Urol; 1987; 13(4):246-50. PubMed ID: 2820737
[TBL] [Abstract][Full Text] [Related]
52. Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer.
Herr HW; Laudone VP; Badalament RA; Oettgen HF; Sogani PC; Freedman BD; Melamed MR; Whitmore WF
J Clin Oncol; 1988 Sep; 6(9):1450-5. PubMed ID: 3418376
[TBL] [Abstract][Full Text] [Related]
53. Positive urinary cytology following a complete response to intravesical bacillus Calmette-Guerin therapy: pattern of recurrence.
Schwalb MD; Herr HW; Sogani PC; Russo P; Sheinfeld J; Fair WR
J Urol; 1994 Aug; 152(2 Pt 1):382-7. PubMed ID: 8015076
[TBL] [Abstract][Full Text] [Related]
54. Flow cytometry as a predictor of response and progression in patients with superficial bladder cancer treated with bacillus Calmette-Guerin.
Bretton PR; Herr HW; Kimmel M; Fair WR; Whitmore WF; Melamed MR
J Urol; 1989 Jun; 141(6):1332-6. PubMed ID: 2724430
[TBL] [Abstract][Full Text] [Related]
55. [Intravesical immunotherapy of in situ carcinoma of the urinary bladder using Bacillus Calmette-Guerin (BCG)].
Jakse G
Wien Klin Wochenschr; 1987 Feb; 99(4):114-8. PubMed ID: 3577186
[TBL] [Abstract][Full Text] [Related]
56. Superficial bladder cancer treated by intravesical bacillus Calmette-Guerin or adriamycin: multicenter study interim report.
Khanna OP; Son DL; Mazer H; Read J; Nugent D; Cottone R; Heeg M; Rezvan M; Viek N; Friedmann M
Urology; 1987 Dec; 30(6):520-8. PubMed ID: 3318089
[TBL] [Abstract][Full Text] [Related]
57. Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: results of treatment with intravesical bacillus Calmette-Guerin.
Hillyard RW; Ladaga L; Schellhammer PF
J Urol; 1988 Feb; 139(2):290-3. PubMed ID: 3339727
[TBL] [Abstract][Full Text] [Related]
58. Influence of fibrin clot inhibitors on the efficacy of intravesical Bacillus Calmette-Guérin in the treatment of superficial bladder cancer. The Dutch Southeast Cooperative Urological Group.
Witjes JA; vd Meijden AP; Doesburg W; Debruyne FM
Eur Urol; 1993; 23(3):366-70. PubMed ID: 8508889
[TBL] [Abstract][Full Text] [Related]
59. Bacillus Calmette-Guérin treatment of 39 patients with superficial transitional cell carcinoma of the bladder.
al Khalifa MA; Elfving P; Månsson W; Colleen S
Scand J Urol Nephrol; 1991; 25(2):135-9. PubMed ID: 1871559
[TBL] [Abstract][Full Text] [Related]
60. Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials.
De Jager R; Guinan P; Lamm D; Khanna O; Brosman S; De Kernion J; Williams R; Richardson C; Muenz L; Reitsma D
Urology; 1991 Dec; 38(6):507-13. PubMed ID: 1836081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
